Silicon Valley startup Queue has emerged from stealth to introduce what it calls the world’s first fully autonomous robotic pharmacy. The company aims to transform prescription fulfillment with a kiosk that dispenses medication without on-site human intervention. Having secured $18.6 million in total funding, Queue is poised to address critical challenges facing the American pharmacy industry.
Addressing a Strained Pharmacy System
The American pharmacy landscape is facing immense pressure, creating an urgent need for innovation. Widespread reports indicate that pharmacists are grappling with overwhelming workloads and significant job dissatisfaction, leading to a severe labor crisis. This situation is worsened by a projected shortfall of thousands of new pharmacy graduates over the next several years.
Economic challenges and workforce shortages have led to a significant reduction in pharmacy access across the country. Researchers found that nearly one in three pharmacies has closed since 2010, creating vast "pharmacy deserts" in many communities. These closures limit patient access to essential medications and place a greater strain on remaining healthcare services.
A New Model for Prescription Fulfillment
Queue's solution is a self-contained robotic system designed to automate the entire prescription dispensing process. The machine accepts sealed wholesale pill bottles, autonomously fills patient-specific vials, and performs verification checks without human assistance. The platform currently supports 250 of the most commonly prescribed medications in the United States.
The company claims its technology can dramatically improve efficiency and reduce operational expenses for pharmacies. By automating the mechanical tasks of counting and bottling pills, the system can reportedly lower dispensing costs by up to 96 percent. This innovation allows pharmacists to focus on patient counseling and other critical clinical responsibilities that require their expertise.
Strategic Funding and Market Validation
Investor confidence in Queue's vision is demonstrated by its recent successful funding rounds. The company closed an oversubscribed $12.6 million seed round led by AlleyCorp, which followed a $6 million pre-seed round from Riot Ventures. This brings the startup's total capital raised to $18.6 million, providing substantial resources for its growth.
Queue plans to use the new capital to accelerate product development and expand its deployments with enterprise pharmacy customers. The company has already secured a major national pharmacy chain as a client and deployed a working prototype for early validation. It is also actively hiring to grow its 20-person engineering team in Silicon Valley.
Experienced Leadership and Investor Outlook
The company is led by a team with a strong track record in both healthcare and advanced engineering. Co-founder and CEO Nick Desai is a seasoned entrepreneur who previously founded the home healthcare company Heal. Co-founder and CTO Josh Liu brings valuable experience from his time at technology firms like Tesla and Zipline.
Investors believe Queue is developing essential infrastructure for the future of healthcare. Abe Murray, General Partner at AlleyCorp, noted that the team has achieved a rare feat in healthcare hardware development. He emphasized that the technology can increase patient access while alleviating the severe labor constraints plaguing pharmacies nationwide.
As Queue moves from development into deployment, it presents a bold vision for the future of prescription fulfillment. The company's autonomous technology promises to enhance efficiency, lower costs, and improve access in a system strained by labor shortages. While navigating regulatory hurdles and proving reliability at scale will be critical, Queue is positioned to modernize healthcare infrastructure.